Prior to his new role, Dr. Hollander served as chief research and development officer at Aerie Pharmaceutical. Dr. Hollander has 20 years of experience in the biotech and pharmaceutical industry, according to the Oct. 17 Revance news release.
“David joins Revance at an exciting time, as we turn our sights towards aesthetics commercial launch, international regulatory strategy, and the advancement of our therapeutics opportunity and biosimilar to Botox program,” Revance President Dustin Sjuts said. “With his proven leadership and extensive background and experience leading global clinical development, regulatory strategies and product life-cycle management, David will augment our capabilities in these areas to support our growth in the years ahead.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.